TNSN05122A1 - Derives de proline presentant une affinite pour la sous-unite alpha-2-delta du canal calcium - Google Patents

Derives de proline presentant une affinite pour la sous-unite alpha-2-delta du canal calcium

Info

Publication number
TNSN05122A1
TNSN05122A1 TNP2005000122A TNSN05122A TNSN05122A1 TN SN05122 A1 TNSN05122 A1 TN SN05122A1 TN P2005000122 A TNP2005000122 A TN P2005000122A TN SN05122 A TNSN05122 A TN SN05122A TN SN05122 A1 TNSN05122 A1 TN SN05122A1
Authority
TN
Tunisia
Prior art keywords
alkyl
disorders
group
amino
alkoxy
Prior art date
Application number
TNP2005000122A
Other languages
English (en)
Inventor
David James Rawson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN05122A1 publication Critical patent/TNSN05122A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LES COMPOSES DE FORMULE (I) OU UN DE LEURS SELS, PRODUITS DE SOLVATATION OU PRECURSEURS MEDICAMENTEUX PHARMACEUTIQUEMENT ACCEPTABLES SONT DES DERIVES DE PROLINE UTILES DANS LE TRAITEMENT DE L'EPILEPSIE, D'ATTAQUES DE LIPOTHYMIE, DE L'HYPOKINESIE, DE TROUBLES CRANIENS, DE TROUBLES NEURODEGENERATIFS, DE LA DEPRESSION, DE L'ANXIETE, DE LA PANIQUE, DE LA DOULEUR, DE LA FIBROMYALGIE, DE L'ARTHRITE, DE TROUBLES NEUROPATHOLOGIQUES, DE TROUBLES DU SOMMEIL, DE TROUBLES DOULOUREUX VISCERAUX ET DE TROUBLE GASTRO-INTESTINAUX. DES PROCEDES POUR LA PREPARATION DES PRODUITS FINALS ET DES INTERMEDIAIRES UTILES DANS LE PROCEDE SONT INCLUS. DES COMPOSITIONS PHARMACEUTIQUES CONTENANT UN OU PLUSIEURS DES COMPOSES SONT EGALEMENT INCLUSES. FORMULE DANS LAQUELLE SOIT X REPRESENTE UN ATOME DE O OU S, UN GROUPE NH OU CH2 ET Y REPRESENTE UN GROUPE CH2 OU UNE LIAISON DIRECTE, SOIT Y REPRESENTE UN ATOME DE O OU S OU UN GROUPE NH, ET X REPRESENTE UN GROUPE CH2; ET R REPRESENTE UN GROUPE CYCLOALKYLE TRI-A DODECAGONAL, HETEROCYCLOALKYLE TETRA- A DODECAGONAL, HETEROARYLE OU ARYLE, N'IMPORTE QUEL NOYAU POUVANT ETRE FACULTATIVEMENT SUBSTITUE AVEC UN OU PAR PLUSIEURS SUBSTITUANTS CHOISIS INDEPENDAMMENT ENTRE DES SUBSTITUANTS HALOGENO, HYDROXY, CYANO, NITRO, AMINO, HYDROXYCARBONYLE, ALKYLE EN C1 A C6, ALCENYLE EN C1 A C6, ALCYNYLE EN C1 A C6, ALKOXY EN C1 A C6, HYDROXYALKYLE EN C1A C6, (ALKOXY EN C1 A C6)(ALKYLE EN C1 A C6), PERFLUORALKYLE EN C1 A C6, PERFLUORALKOXY EN C1 A C6, ALKYLAMINO EN C1 A C6, DI (ALKYLE EN C1 A C6) AMINO, AMINOALKYLE EN C1 A C6, (ALKYLE EN C1 A C6) AMINO (ALKYLE EN C1 A C6), DI (ALKYLE EN C1 A C6), AMINO (ALKYLE EN C1 A C6), ACYLE EN C1 A C6, ACYLOXY EN C1 A C6, (ACYLE EN C1 A C6) OXY (ALKYLE EN C1 A C6), ACYLAMINO EN C1 A C6, ALKYLTHIO EN C1 A C6, (ALKYLE EN C1 A C6) THIOCARBONYLE, ALKYLTHIOXO EN C1 A C6, (ALKOXY EN C1 A C6) CARBONYLE, ALKYLSULFONYLE EN C1 A C6, ALKYLSULFONYLAMINO EN C1 A C6, AMINOSULFONYLE, ALKYLAMINOSULFONYLE EN C1 A C6, DI (ALKYLE EN C1 A C6) AMINOSULFONYLE, CYCLOALKYLE TRI- A OCTOGONAL, HETEROCYCLOALKYLE TETRA- A OCTOGONAL, PHENYLE ET HETEROARYLE MONOCYCLIQUE ; OU UN SEL PRODUIT DE SOLVATATION OU PRECURSEUR MEDICAMENTEUX PHARMACEUTIQUEMENT ACCEPTABLE DE CES COMPOSES.
TNP2005000122A 2002-10-31 2005-04-29 Derives de proline presentant une affinite pour la sous-unite alpha-2-delta du canal calcium TNSN05122A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0225379.7A GB0225379D0 (en) 2002-10-31 2002-10-31 Therapeutic proline derivatives
PCT/IB2003/004697 WO2004039367A1 (fr) 2002-10-31 2003-10-22 Derives de proline presentant une affinite pour la sous-unite alpha-2-delta du canal de calcium

Publications (1)

Publication Number Publication Date
TNSN05122A1 true TNSN05122A1 (fr) 2007-05-14

Family

ID=9946940

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2005000122A TNSN05122A1 (fr) 2002-10-31 2005-04-29 Derives de proline presentant une affinite pour la sous-unite alpha-2-delta du canal calcium

Country Status (39)

Country Link
EP (1) EP1558246B1 (fr)
JP (2) JP3940416B2 (fr)
KR (2) KR100750782B1 (fr)
CN (1) CN100418525C (fr)
AP (1) AP2005003295A0 (fr)
AR (1) AR041865A1 (fr)
AT (1) ATE468116T1 (fr)
AU (1) AU2003269411B2 (fr)
BR (1) BR0315839A (fr)
CA (1) CA2499698C (fr)
CO (1) CO5550430A2 (fr)
CR (1) CR7802A (fr)
DE (1) DE60332646D1 (fr)
DK (1) DK1558246T3 (fr)
EA (1) EA009767B1 (fr)
EC (1) ECSP055769A (fr)
ES (1) ES2343624T3 (fr)
GB (1) GB0225379D0 (fr)
GE (1) GEP20074127B (fr)
GT (1) GT200300234A (fr)
HK (1) HK1081441A1 (fr)
HR (1) HRP20050351A2 (fr)
IL (4) IL167799A (fr)
IS (1) IS7754A (fr)
MA (1) MA27481A1 (fr)
MX (1) MXPA05004662A (fr)
NL (1) NL1024677C2 (fr)
NO (1) NO330496B1 (fr)
OA (1) OA12954A (fr)
PA (1) PA8587201A1 (fr)
PE (1) PE20040553A1 (fr)
PL (1) PL376703A1 (fr)
RS (1) RS20050333A (fr)
TN (1) TNSN05122A1 (fr)
TW (2) TW200416030A (fr)
UA (1) UA81437C2 (fr)
UY (1) UY28043A1 (fr)
WO (1) WO2004039367A1 (fr)
ZA (1) ZA200502305B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0225379D0 (en) * 2002-10-31 2002-12-11 Pfizer Ltd Therapeutic proline derivatives
US20050043345A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
WO2005097741A1 (fr) * 2004-04-05 2005-10-20 Pfizer Limited Procédé de recristallisation de dérivés de la proline
WO2006092692A1 (fr) * 2005-03-01 2006-09-08 Pfizer Limited Utilisation d'associations d’inhibiteurs de pde7 et de ligands alpha-2-delta pour le traitement de la douleur neuropathique
WO2007142028A1 (fr) 2006-06-06 2007-12-13 Gifu University Analogue de pyrrolidine pour la prévention de la douleur neurogène et sa méthode de production
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
EP2919788A4 (fr) 2012-11-14 2016-05-25 Univ Johns Hopkins Méthodes et compositions pour le traitement de la schizophrénie
JP2016523266A (ja) 2013-06-26 2016-08-08 浙江九洲▲藥▼▲業▼股▲ふぇん▼有限公司 ピロリジン−２−カルボン酸誘導体の調製方法
WO2015003723A1 (fr) * 2013-07-12 2015-01-15 Københavns Universitet Dérivés substitués de 4-proline en tant qu'antagonistes iglur
CN104418785A (zh) * 2013-09-05 2015-03-18 浙江九洲药业股份有限公司 一种药物中间体的制备方法
CN104829513B (zh) * 2014-02-11 2019-02-19 浙江九洲药业股份有限公司 一种2-羧基-4-甲氧基甲基吡咯烷衍生物的制备方法
CN104844495A (zh) * 2015-06-05 2015-08-19 武汉理工大学 一种(2s,4s)-4-苯硫基-l-脯氨酸盐酸盐的合成方法
TW202026281A (zh) * 2018-12-12 2020-07-16 西班牙商艾斯提夫製藥股份有限公司 用於治療疼痛和疼痛相關病症之新吡咯啶–2– 甲酸衍生物
WO2020120606A1 (fr) * 2018-12-12 2020-06-18 Esteve Pharmaceuticals, S.A. Nouveaux dérivés d'acide pyrrolidine-2-carboxylique pour le traitement de la douleur et d'états pathologiques associés à la douleur
EP3904339A1 (fr) * 2020-04-28 2021-11-03 Esteve Pharmaceuticals, S.A. Dérivés d'alkylaminoproline en tant que bloqueurs alfa-2-delta-1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316906A (en) * 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
CA1144930A (fr) * 1978-08-11 1983-04-19 Miguel A. Ondetti Derives mercaptoacyles de prolines substituees
US4311705A (en) * 1980-10-06 1982-01-19 E. R. Squibb & Sons, Inc. Carboxyalkanoyl and hydroxycarbamoylalkanoyl derivatives of substituted prolines
ZA817601B (en) * 1980-11-24 1982-10-27 Squibb & Sons Inc Carboxyalkyl amino acid derivatives of various substituted prolines
AU1873992A (en) * 1991-04-19 1992-11-17 Nova Technology Limited Partnership Bradykinin antagonist peptides
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US6156726A (en) * 1996-08-02 2000-12-05 Elan Pharmaceuticals, Inc. Voltage-gated calcium channel antagonist and method
JP3196106B2 (ja) * 1997-03-27 2001-08-06 参天製薬株式会社 ロイコトリエンａ４ヒドロラーゼ阻害剤
CA2322558C (fr) * 1998-05-26 2006-04-11 Warner-Lambert Company Composes d'acide amines soumis a une contrainte de conformation et presentant une affinite pour la sous-unite alpha 2 delta d'un canal calcique
CO5300399A1 (es) * 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
GB0225379D0 (en) * 2002-10-31 2002-12-11 Pfizer Ltd Therapeutic proline derivatives

Also Published As

Publication number Publication date
ZA200502305B (en) 2006-11-29
ATE468116T1 (de) 2010-06-15
JP2006516115A (ja) 2006-06-22
EA009767B1 (ru) 2008-04-28
EA200500581A1 (ru) 2005-12-29
RS20050333A (en) 2007-06-04
KR20070046213A (ko) 2007-05-02
GB0225379D0 (en) 2002-12-11
CR7802A (es) 2007-10-23
HK1081441A1 (en) 2006-05-19
HRP20050351A2 (en) 2005-10-31
CN100418525C (zh) 2008-09-17
IL201965A (en) 2011-03-31
IL201966A (en) 2011-06-30
KR100750782B1 (ko) 2007-08-20
NO20051407L (no) 2005-07-26
DE60332646D1 (de) 2010-07-01
BR0315839A (pt) 2005-09-27
CA2499698C (fr) 2009-01-20
AP2005003295A0 (en) 2005-06-30
IL201967A (en) 2011-06-30
PA8587201A1 (es) 2004-05-26
UY28043A1 (es) 2004-05-31
ECSP055769A (es) 2005-08-11
CA2499698A1 (fr) 2004-05-13
CN1711081A (zh) 2005-12-21
JP2006328078A (ja) 2006-12-07
WO2004039367A1 (fr) 2004-05-13
ES2343624T3 (es) 2010-08-05
GEP20074127B (en) 2007-06-11
TW200633699A (en) 2006-10-01
TW200416030A (en) 2004-09-01
PL376703A1 (pl) 2006-01-09
PE20040553A1 (es) 2004-08-28
UA81437C2 (en) 2008-01-10
AU2003269411A1 (en) 2004-05-25
CO5550430A2 (es) 2005-08-31
NL1024677A1 (nl) 2004-05-06
KR20050065646A (ko) 2005-06-29
EP1558246A1 (fr) 2005-08-03
JP3940416B2 (ja) 2007-07-04
IS7754A (is) 2005-03-17
DK1558246T3 (da) 2010-08-09
NO330496B1 (no) 2011-05-02
AU2003269411B2 (en) 2009-06-18
JP4555263B2 (ja) 2010-09-29
MA27481A1 (fr) 2005-08-01
NO20051407D0 (no) 2005-03-17
OA12954A (en) 2006-10-13
MXPA05004662A (es) 2005-06-08
IL167799A (en) 2011-03-31
GT200300234A (es) 2004-06-23
AR041865A1 (es) 2005-06-01
EP1558246B1 (fr) 2010-05-19
NL1024677C2 (nl) 2005-07-04

Similar Documents

Publication Publication Date Title
TNSN05122A1 (fr) Derives de proline presentant une affinite pour la sous-unite alpha-2-delta du canal calcium
TNSN98237A1 (fr) Composes azapolycycliques a noyau aryle condense, procede pour leur preparation et compositions pharmaceutiques les contenant
US11780805B2 (en) Carbamoyl phenylalaninol compounds and uses thereof
MXPA01006474A (es) Derivados colquinol como agentes perjudiciales vasculares.
TNSN05165A1 (fr) Derives de pyrrolopyrimidine
HUP0401889A2 (hu) 1,8-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények
EA200870384A1 (ru) 3,7-диамино-10h-фенотиазиновые соли и их применение
RS28004A (en) Azabicycle-substituted fused- heteroaryl compounds for the treatment of disease
WO1982003859A1 (fr) Derives de 1-sulfo-2-oxoazetidine et procede de preparation
US6946474B2 (en) Nitrogen-containing compounds and their use as glycine transport inhibitors
SG151336A1 (en) 1,3,4-oxadiazol-2-ones as ppar delta
IL178167A0 (en) 1,3,4-oxadiazol-2-ones as ppar delta modulators
TNSN98151A1 (fr) Derives de 2 - (4 - aryl - ou heteroaryl - piperazine - 1 - ylmethyl) -1 h - indole.
HUP0100520A1 (hu) Csontfelszívódást és sejtösszenövést gátló új szulfonamidszármazékok
HUP0401080A2 (hu) Új görcsoldó sószármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ATE224893T1 (de) Pyrazolopyridinverbindung und seine pharmazeutische verwendung
US20240317789A1 (en) Prodrugs of tapinarof
FR2765578B1 (fr) Procede de preparation d'un perhydroisoindole substitue
MA27795A1 (fr) Derives d'amine cycliques, procedes de preparation de ceux-ci et compositions pharmaceutiques les contenant
TNSN99080A1 (fr) Composes azapolycycliques condenses a noyau aryle, procede pour leur preparation et compositions pharmaceutiques les contenant
CN105658625A (zh) 作为细胞坏死阻碍剂的吲哚酰胺化合物
FI964482A (fi) Amidijohdannaisia ja niiden käyttö lääkkeenä
ATE169635T1 (de) Therapeutische verbindungen für die behandlung von krankheiten, die mit einem glutathion-defizit assoziiert sind, herstellungsprozess und diese enthaltene pharmazeutische zusammensetzungen
US4029807A (en) Compounds 5-hydroxytryptophan glutamate and its derivatives
RU2322438C2 (ru) Азаспиросоединения для лечения болей